<SEC-DOCUMENT>0001193125-23-263207.txt : 20231026
<SEC-HEADER>0001193125-23-263207.hdr.sgml : 20231026
<ACCEPTANCE-DATETIME>20231025173127
ACCESSION NUMBER:		0001193125-23-263207
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231025
FILED AS OF DATE:		20231026
DATE AS OF CHANGE:		20231025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		231346954

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d915306d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;25, 2023 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35203</FONT> </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 Peel
Street, Suite 1100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montr&eacute;al, Qu&eacute;bec, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H3A 1T8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&#8194;&#9744;&#8195;&#8195;&#8195;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&#8194;&#9746;</FONT> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1): </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check
mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR.
</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule
<FONT STYLE="white-space:nowrap">12g3-2(b):</FONT> <FONT STYLE="white-space:nowrap">82-______________.</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THERATECHNOLOGIES INC. </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release Dated October&nbsp;25, 2023</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THERATECHNOLOGIES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel and Corporate Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&nbsp;25, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d915306dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g915306g1026022831962.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>This news release constitutes a &#147;designated news release&#148; for the purposes of the Company&#146;s prospectus supplement
dated December&nbsp;16, 2021 to its short form base shelf prospectus dated December&nbsp;14, 2021. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Montreal, Quebec,
October</B><B></B><B>&nbsp;25, 2023 </B>&#150; Theratechnologies Inc. (&#147;Theratechnologies&#148; or the &#147;Company&#148;) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative
therapies, today announced the launch of a marketed public offering (the &#147;Public Offering&#148;) of common shares of the Company (the &#147;Common Shares&#148;). The Company intends to grant the underwriter a
<FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 15% of the number of Common Shares to be sold pursuant to the Public Offering (the &#147;Option&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering, the Company intends to enter into a subscription agreement with Investissement Qu&eacute;bec for a concurrent private
placement of Common Shares (and Common Share equivalents in the form of <FONT STYLE="white-space:nowrap">pre-funded,</FONT> <FONT STYLE="white-space:nowrap">non-voting</FONT> subscription receipts, exchangeable into Common Shares on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (the &#147;Exchangeable Subscription Receipts&#148;) in lieu of Common Shares), for up to US$12.5&nbsp;million aggregate gross proceeds (the &#147;Concurrent
Private Placement&#148;). As part of the Concurrent Private Placement, it is expected that Investissement Qu&eacute;bec will be granted rights to nominate one director to the Company&#146;s board of directors. The consummation of the Concurrent
Private Placement will be contingent upon the closing of the Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.&nbsp;is acting as the underwriter for the
Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A preliminary prospectus supplement (the &#147;Prospectus Supplement&#148;) to the Company&#146;s short form base shelf prospectus dated
December&nbsp;14, 2021 (the &#147;Base Shelf Prospectus&#148;) was filed with the securities regulatory authorities in each of the provinces of Canada as well as with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) as part of its
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-10</FONT> (the &#147;Registration Statement&#148;) under the U.S.-Canada multijurisdictional disclosure system (&#147;MJDS&#148;). The Public Offering will be made in Canada only
pursuant to the Prospectus Supplement and Base Shelf Prospectus and in the United States<B> </B>only pursuant to the Registration Statement, containing the Prospectus Supplement and the Base Shelf Prospectus, filed with the SEC under the MJDS.
Copies of the Prospectus Supplement and the Base Shelf Prospectus are available on SEDAR+ at <U>www.sedarplus.ca</U> and on EDGAR at <U>www.sec.gov</U>, and a copy of the Registration Statement is available on EDGAR at <U>www.sec.gov</U>. Copies may
also be obtained from Cantor Fitzgerald&nbsp;&amp; Co., Attention: Capital Markets,&nbsp;110 East 59th Street, 6th Floor,&nbsp;New York, New York&nbsp;10022, or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at&nbsp;<U>prospectus@cantor.com</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Completion of the Public Offering and Concurrent Private Placement will be subject to customary closing conditions, including the listing of the Common
Shares and the Common Shares underlying the Exchangeable Subscription Receipts on the Toronto Stock Exchange and the submission of notice to the Nasdaq Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective investors should read the Prospectus Supplement, Base Shelf Prospectus and Registration Statement before making an investment decision. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities regulatory authority has either approved or disapproved the contents of this news release.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such province, state or jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Theratechnologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing
unmet medical needs. Further information about Theratechnologies is available on the Company&#146;s website at <U>www.theratech.com</U>, on SEDAR+ at <U>www.sedarplus.ca</U> and on EDGAR at <U>www.sec.gov</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements and forward-looking information (collectively, the &#147;Forward-Looking Statements&#148;) within the meaning of applicable securities laws, that are based on management&#146;s beliefs and assumptions and on information
currently available to it. You can identify forward-looking statements by terms such as &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;could&#148;, &#147;promising&#148;, &#147;would&#148;, &#147;outlook&#148;, &#147;believe&#148;,
&#147;plan&#148;, &#147;envisage&#148;, &#147;anticipate&#148;, &#147;expect&#148; and &#147;estimate&#148;, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not
limited to, statements regarding the sale of Common Shares and the Exchangeable Subscription Receipts; the Public Offering, including its size, price and the closing thereof; the underwriting agreement; the granting to the underwriter of the Option;
the Concurrent Private Placement, including its size, price and the closing thereof; and the subscription agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Forward-Looking
Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual
results may vary from the Forward-Looking Statements. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company&#146;s control, that could cause actual results to differ
materially from those that are disclosed in or implied by such Forward-Looking Statements. These, as well as other, risks and uncertainties are described more fully in the section titled &#147;Risk Factors&#148; of the preliminary Prospectus
Supplement and of the Base Shelf Prospectus in connection with the Public Offering as well as other public filings made by the Company available on SEDAR+ at <U>www.sedarplus.ca</U> and on EDGAR at <U>www.sec.gov</U>. The reader is cautioned to
consider these and other risks and uncertainties carefully and not to put undue reliance on Forward-Looking Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-Looking Statements reflect current expectations regarding future events and speak only as of the
date of this press release and represent the Company&#146;s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events
or circumstances or otherwise, except as may be required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor inquiries: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philippe Dubuc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>pdubuc@theratech.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-438-315-6608</FONT></FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media inquiries: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julie Schneiderman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Communications&nbsp;&amp;
Corporate Affairs </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>communications@theratech.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-514-336-7800</FONT></FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g915306g1026022831962.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915306g1026022831962.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ *,# 2(  A$! Q$!_\0
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M>'M8\-WFFV4=Q=SW";(PT)55/9N>XZ\5N_"W2+W2?";"^B>%[F=IDB<895(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
